AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9692698
Drug: Mosapride 40
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride 40 mg q.d.s. for 2 days
Trial: 7919152
Drug: Caffeine (adenosine-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (adenosine-receptor antagonist)
Trial: 3079536
Drug: Oral glucose/electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose/electrolyte solution designed for maintenance of hydration (Na+ concentration 45 mmol/l)
Trial: 3079536
Drug: Oral glucose/electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose/electrolyte solution designed for fluid replacement (Na+ concentration 75 mmol/l)
Trial: 11557312
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (12.5 mg/kg body weight) and N-acetyl-cysteine (10 mg/kg body weight) for 7 days
Trial: 9663892
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 5 mg folic acid daily for 40 weeks
Trial: 9663892
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 5 mg folic acid daily for 52 weeks
Trial: 7852661
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg cyanocobalamin (3 x/day)
Trial: 23090813
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Methylphenidate (MPH)
Trial: 23300127
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy for Antidepressants (META)
Trial: 21361737
Drug: Ingesting 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingesting 10 tablets (four acetaminophen, four ibuprofen, and two multivitamin tablets) with 500 ml of water
Trial: 21361737
Drug: Drinking 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking 500 ml of water alone (control group)
Trial: 12538743
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg orally for 6 weeks)
Trial: 12538743
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg orally for 6 weeks)
Trial: 12538743
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antihypertensive drugs except diuretics)
Trial: 11195946
Drug: Concurrent knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent knowledge of clinical ear status
Trial: 3812946
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml 0.5% prilocaine
Trial: 3812946
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 1% prilocaine
Trial: 3812946
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml 1% prilocaine
Trial: 3812946
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg prilocaine
Trial: 29575488
Drug: Internal connection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal connection and microthreads on the implant neck (I MT)
Trial: 26345106
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing plus 375 mg amoxicillin and 250 mg metronidazole for 7 days
Trial: 23905537
Drug: Therapist responsiveness
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist responsiveness in the first two sessions of therapy (Cognitive Behavior Therapy and Interpersonal Psychotherapy)
Trial: 20124051
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate therapy for 28 days
Trial: 20124051
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate therapy
Trial: 19103540
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) added to induction cardioplegia solution at a dose of 4 mmol/l and to maintenance cardioplegia solution at a dose of 2 mmol/l
Trial: 11127492
Drug: Educational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational group sessions and individual sessions administered by a trained nurse and physiotherapist for COPD patients.
Trial: 3101243
Drug: Intramuscular iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iron dextran prophylaxis
Trial: 29089053
Drug: Fluralaner (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner (1.5 mg/kg body weight, 4 administrations, 7 days apart)
Trial: 24019110
Drug: Colesevelam (3,750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3,750 mg once daily) administered simultaneously with glimepiride
Trial: 24019110
Drug: Colesevelam (3,750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3,750 mg once daily) administered simultaneously with glipizide ER
Trial: 24019110
Drug: Colesevelam (3,750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3,750 mg once daily) administered simultaneously with olmesartan medoxomil
Trial: 24019110
Drug: Colesevelam (3,750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3,750 mg once daily) administered 4 hours before glimepiride
Trial: 24019110
Drug: Colesevelam (3,750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3,750 mg once daily) administered 4 hours before glipizide ER
Trial: 24019110
Drug: Colesevelam (3,750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (3,750 mg once daily) administered 4 hours before olmesartan medoxomil
Trial: 21781231
Drug: Zinc-aluminium ointment
RxNorm normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc-aluminium ointment
Trial: 20087302
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (0.8% BCAA in a 3.5% carbohydrate solution; 2,500 mL/day)
Trial: 17535868
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated TS)
Trial: 9168213
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg administered directly in the surgical site (mixed with local anesthetic)
Trial: 9168213
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg administered via the parenteral route
Trial: 1438525
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg b.d.) with MMSC (500 mg four times daily)
Trial: 1438525
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg b.d.) with cysteine (200 mg four times daily)
Trial: 1438525
Drug: Cimetidine alone
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine alone (previous treatment)
Trial: 2410683
Drug: Prazosin (5.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (5.7 mg/day)
Trial: 25515163
Drug: Classical method
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical method of esophageal speech therapy
Trial: 23808506
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (bolus of 8 to 15 ml of ropivacaine 0.2% and infusion of 5 to 15 ml/hour for three days)
Trial: 23808506
Drug: Transversus abdominis
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus abdominis plane block (bolus dose of 20 ml of ropivacaine 0.375% bilaterally and infusion of 0.2% ropivacaine 8 ml/hour bilaterally for three days)
Trial: 20623443
Drug: Fiber-free diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber-free diet (FFD) with polyethylene glycol electrolyte solution (PEG-ES)
Trial: 20623443
Drug: Clear-liquid diet
RxNorm normalized name: Metamucil Clear & Natural Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear-liquid diet (CLD) with polyethylene glycol electrolyte solution (PEG-ES)
Trial: 18972726
Drug: Chinese drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drug Yueyue-shu (Control)
Trial: 16377669
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg) alone
Trial: 16377669
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg) with antacid (Maalox containing 600 mg magnesium hydroxide and 900 mg aluminum hydroxide)
Trial: 12754130
Drug: Methotrexate 12.3±3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 12.3±3.6 mg once a week + Meloxicam 7.5 mg for 3 months
Trial: 12754130
Drug: Methotrexate 21.3±3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 21.3±3.2 mg once a week + Meloxicam 7.5 mg for 3 months
Trial: 1330676
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (0.5 mg/ml)
Trial: 1330676
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (2.5 mg/ml)
Trial: 1330676
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (10 mg/ml)
Trial: 31095117
Drug: 20 mL 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.5% ropivacaine and 1 ug/kg of dexmedetomidine (group RD)
Trial: 31095117
Drug: 20 mL 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.5% ropivacaine (group R)
Trial: 28339165
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate nasal spray
Trial: 16216821
Drug: Self management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self management using a point of care device to measure INR twice a week and a dosing chart
Trial: 14589256
Drug: Medical care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical care plus physical therapy
Trial: 10541320
Drug: Maternal receipt
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal receipt of antibiotic in the 24 hours before delivery
Trial: 2339012
Drug: lidocaine 5
RxNorm normalized name: lidocaine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 5 mg/kg
Trial: 24197584
Drug: Levosimendan therapy
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan therapy
Trial: 19187340
Drug: PGE(2) infusion
RxNorm normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE(2) infusion (0.40 microg kg(‐1) min(‐1))
Trial: 11536222
Drug: Modified-release (MR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release (MR) dosage forms of metformin
Trial: 11536222
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) dosage forms of metformin
Trial: 11536222
Drug: Modified-release (MR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release (MR) formulations of metformin
Trial: 11536222
Drug: Extended convolution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended convolution approach modeling absorption using a Hill function
Trial: 9340970
Drug: Platinum containing
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum containing re‐induction chemotherapy
Trial: 9340970
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment (tamoxifen or GnRH analogues)
Trial: 9340970
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with topoisomerase blocking agents, taxanes, or alkylating agents
Trial: 8485203
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for AML M4Eo
Trial: 23528580
Drug: Mexidol (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (375 mg daily)
Trial: 23528580
Drug: Antidepressants (fevarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (fevarin 150 mg daily)
Trial: 18950383
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dose of amitriptyline
Trial: 16192503
Drug: Clamp‐crushing method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clamp‐crushing method (CC group)
Trial: 12452403
Drug: Hypnosis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis treatment (seven biweekly sessions and home audiotapes)
Trial: 2755712
Drug: Hypnosis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis treatment
Trial: 10599010
Drug: Intensive counselling
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive counselling at the start of treatment and at each subsequent visit for ambulatory patients, or weekly for hospitalised patients.
Trial: 7075566
Drug: New simpler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New simpler oral cleansing preparation
Trial: 31962346
Drug: Biofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback treatment for primary headache (8-11 sessions, including vasoconstriction/vasodilation training for migraine and electromyography training for tension-type headache)
Trial: 31962346
Drug: Waiting control
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting control group (no treatment)
Trial: 29985874
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (EES) at a dose of 50 mg . kg . day
Trial: 27684813
Drug: Tablet-based box
RxNorm normalized name: ALLERGENIC EXTRACT, BOX ELDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based box trainer (TBT)
Trial: 24909799
Drug: β-cryptoxanthin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-cryptoxanthin (0.75 mg/day) plus phytosterols (1.5 g/day)
Trial: 24909799
Drug: β-cryptoxanthin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-cryptoxanthin (0.75 mg/day)
Trial: 24909799
Drug: phytosterols (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phytosterols (1.5 g/day)
Trial: 23043951
Drug: Prostaglandin F
RxNorm normalized name: Prostaglandin F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F (PGF) 2 mL per fish in 2009/2010 season and 5 mL per fish in 2010/2011 season, in addition to carp pituitary extract (6 mg/kg)
Trial: 23043951
Drug: Carp pituitary
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carp pituitary extract (6 mg/kg)
Trial: 12431041
Drug: Ketotifen fumarate
RxNorm normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketotifen fumarate .025% ophthalmic solution
Trial: 1299590
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment only (Group A)
Trial: 1299590
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g GL intravenously 15 min before thrombolysis (Group B)
Trial: 1299590
Drug: 6.25 mg
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.25 mg CA orally 15 min before thrombolytic treatment (Group C)
Trial: 1299590
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g GL intravenously before thrombolysis and 6.25 mg CA orally (Group D)
Trial: 6380554
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bd tamoxifen
Trial: 6380554
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bd tamoxifen
Trial: 27156934
Drug: Tocilizumab 162
RxNorm normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 162 mg subcutaneously weekly
Trial: 22800352
Drug: Anti-acid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-acid therapy and conventional pharyngo-laryngitis therapy in LPR group
Trial: 22800352
Drug: Anti-acid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-acid therapy and conventional pharyngo-laryngitis therapy in control group
Trial: 20394491
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% combined with fluticasone
Trial: 18759257
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg (group 2)
Trial: 18759257
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by infliximab 5 mg/kg (group 1)
Trial: 15897310
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham ultrasound and non-therapeutic gel)
Trial: 8592224
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate 6 mg/kg per day
Trial: 8592224
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate 0.6 mg/kg per day
Trial: 8592224
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate 2 mg/kg per day
Trial: 1868479
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment alone for reflux grade III or less
Trial: 1868479
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment alone for reflux grade IV (control group)
Trial: 6202972
Drug: Aspirin, 300
RxNorm normalized name: Aspirin, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 300 mg three times a day for 7 days
Trial: 30614823
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg loading, followed by 90 mg twice daily
Trial: 17763834
Drug: Prophylactic anticonvulsants
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticonvulsants
Trial: 17763834
Drug: Seizure prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seizure prophylaxis with antiepileptic drugs
Trial: 17763834
Drug: Literature on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Literature on prophylactic anticonvulsants
Trial: 11232739
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care programme
Trial: 11232739
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pharmaceutical care)
Trial: 9288859
Drug: 5‐ASA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA (4 g/day Pentasa)
Trial: 3471376
Drug: Weekly 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 0.2% neutral NaF rinse
Trial: 30954486
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid (UA) treatment (16 mg/kg)
Trial: 21371292
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ASA (stopping ASA five days prior to surgery and starting on postoperative day 5)
Trial: 2574050
Drug: Sufotidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufotidine 600 mg once daily
Trial: 2574050
Drug: Sufotidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufotidine 600 mg twice daily
Trial: 23793032
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving weekly reminders to continue their usual physical activities
Trial: 19533164
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks
Trial: 19533164
Drug: Lower limb
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower limb resistance training (RT) at 80% of one repetition maximum, twice each week for 10 weeks